ORPHA:254504
Inhalational botulism
Also known as: Inhalation botulism
Publications
124
60.3th percentile
Trials
0
Interventional, condition-specific
Researchers
528
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Inhalational botulism is a man-made form of botulism, a rare acquired neuromuscular junction disease with descending flaccid paralysis caused by botulinum neurotoxins (BoNTs).
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016777
- UMLS:C1443900
Additional Mondo synonyms (1)
inhalation botulism
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
124 matched papers (71 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 17 for broader category botulism
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
124
124 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
124 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
71 in the last 10 years · high confidence · 60.3th percentile (publications denominator)
Phrase hits: 124 · MeSH hits: 0
Who's working on it?
528
Distinct author names in 124 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Rasetti-Escargueil C5 papers · 2024
Institut Pasteur, Département de Microbiologie, Unité des Toxines Bactériennes, 25 Rue du Docteur Roux, 75015 Paris, France. christine.rasetti-escargueil@pasteur.fr.
Papers in Europe PMC - 02Niemuth N4 papers · 2021
Battelle Biomedical Research Center, West Jefferson, Columbus, OH 43162, USA.
Papers in Europe PMC - 03Popoff MR4 papers · 2022
Institut Pasteur, Département de Microbiologie, Unité des Toxines Bactériennes, 25 Rue du Docteur Roux, 75015 Paris, France. michel-robert.popoff@pasteur.fr.
Papers in Europe PMC - 04Sobel J4 papers · 2021
Foodborne and Diarrheal Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. jsobel@cdc.gov
Papers in Europe PMC - 05Anniballi F3 papers · 2021
National Reference Centre for Botulism, Microbiological Foodborne Hazard Unit, Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, viale Regina Elena, 29900161 Rome, Italy.
Papers in Europe PMC - 06Baka A3 papers · 2019
Task Force on Biological and Chemical Agent Threats, Public Health Directorate, European Commission, Luxembourg.
Papers in Europe PMC - 07Bossi P3 papers · 2006
Department of Infectious Diseases, Pitié-Salpêtrière Hospital, 47-83 Bd de l'Hôpital, 75013, Paris, France. philippe.bossi@psl.ap-hop-paris.fr
Papers in Europe PMC - 08Cobb RR3 papers · 2021
National Resilience, Inc., 13200 NW, Nano Ct, Alachua, FL 32615, USA.
Papers in Europe PMC - 09Farr-Jones S3 papers · 2021
Department of Anesthesia and Perioperative Care, University of California, 1001 Potrero Ave., San Francisco, CA 94110, USA.
Papers in Europe PMC - 10Guillier L3 papers · 2023
ANSES, Risk Assessment Department, Maisons-Alfort, France.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 17 trials are registered for botulism, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
17 interventional trials matched botulism, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: botulism
17
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06580236·NOT YET RECRUITING·Study of the Drug B11-FC (Botulism Treatment)
Conditions: Botulism·Matched via name phrase
- NCT02051062·ENROLLING BY INVITATION·BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
Conditions: Botulism·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Inhalational botulism" OR "Inhalation botulism"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Inhalational botulism" OR "Inhalation botulism"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"botulism"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:04:14.596Z